×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Experiment: AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
experiment
554 words
KG: Ad
2026-03-26
kind:experiment
section:experiments
state:published
Contents
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Individuals Never Develop Dementia
Knowledge Graph
Related Hypotheses (18)
Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.50
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE-TREM2 Interaction Modulation
Score: 0.48
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
APOE Isoform Conversion Therapy
Score: 0.44
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
Show 13 more
Related Analyses (10)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Show 5 more
Related Experiments (30)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Show 25 more
Knowledge Graph (1 edges)
TDP-43
associated_with
Ad